However, while VEGF-A inhibition improves anti-cancer drug access to the tumor tissue, it has also been shown to reduce tissue oxygenation and induce acute hypoxia in diseased tissue in patients with cancer (Bonekamp et al., 2017; Ueda et al., 2017), unlike the observation within bevacizumab-treated pulmonary TB lesions in rabbits (Datta et al., 2015). The gene discussed is VEGFA; the disease is cancer.